Direct oral anticoagulants are increasingly used in clinical practice and have addressed many of the issues related to vitamin K antagonists. However, the lack of reversal in life-threatening situations raises concerns regarding patient...
Read the latest publication digest "A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus?".
Read the latest publication digest "Anticoagulation reversal for intracranial haemorrhage in the era of the direct oral anticoagulants".
In patients taking oral anticoagulants (OACs), the annual rate of intracranial hemorrhage is 0.3% to 0.6%. Of these bleeds, 46% to 86% are intracerebral; 13% to 45% are subdural, and 1% to 8% are subarachnoidal.
This retrospective analysis of data collected from a US Level II trauma centre attempts to determine the effect of international normalised ratio reversal time on haemorrhage evolution in traumatic brain injury patients taking prehospital anticoagulants.
This review article examines the current evidence for reversal of non-vitamin K oral anticoagulants.
Read the latest publication digest "Managing bleeds related to oral factor Xa inhibitors with andexanet alfa or replacement agents".
Direct oral anticoagulants (DOACs) include dabigatran etexilate, a direct thrombin inhibitor, and specific inhibitors of activated coagulation factor X (FXa; e.g. apixaban, betrixaban, edoxaban, rivaroxaban).
A survey of practising paediatric haematologists explores preferences and perspectives surrounding the need for oral anticoagulant reversal after treatment with direct oral anticoagulants.
Read the latest digest detailing "Reversal of direct oral anticoagulants" in the Oral anticoagulation reversal Learning Zone.